Details for Patent: 9,403,799

Which drugs does patent 9,403,799 protect, and when does it expire?

Patent 9,403,799 protects TEPMETKO and is included in one NDA.

This patent has seventy-six patent family members in thirty-five countries.

Summary for Patent: 9,403,799

Title:	Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Abstract:	Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
Inventor(s):	Schadt; Oliver (Rodenbach, DE), Dorsch; Dieter (Ober-Ramstadt, DE), Stieber; Frank (Heidelberg, DE), Blaukat; Andree (Schriesheim, DE)
Assignee:	MERCK PATENT GMBH (Darmstadt, DE)
Application Number:	14/602,921
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 9,403,799

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	TEPMETKO	tepotinib hydrochloride	TABLET;ORAL	214096-001	Feb 3, 2021		RX	Yes	Yes						TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB

International Family Members for US Patent 9,403,799

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	066543
Argentina	067505
Australia	2008274534